Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide LAR for GI Bleeding in HHT
NCT02874326Phase 2Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2016
- Primary completion
- Jul 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of octreotide in hereditary hemorrhagic telangiectasia (HHT), sponsored by Radboud University Medical Center. Primary endpoint: Response to treatment (Complete, Partial, Non-response) at 26 weeks. Status: unknown.
02
Drugs
octreotide
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT02874326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02874326.